Weight-loss headlines often focus on kilograms lost. Before starting a medicine, you also need to know the health goal, who will monitor treatment, the ongoing cost and what to do about side effects. Use these questions for a medical discussion rather than choosing a product or dose yourself.
Key takeaways
- WHO issued conditional guidance for GLP-1 treatment of adult obesity in December 2025 and continued work on the topic in 2026.
- Medicines belong within continuing care that includes food, activity and follow-up. Results cannot be guaranteed.
- Pregnancy plans, other medicines and product-specific warnings need to be discussed before treatment.
- Mentioning these medicines does not establish that Mongkhondee Clinic supplies or administers them.
What are these medicines?
These treatments act through hormone pathways involved in blood sugar and appetite. They are not all identical: semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on GIP and GLP-1 receptors. Products can differ in indications and instructions, even when the active ingredient is familiar. Do not swap pens yourself.
Sources: [2] WHO, [4] MedlinePlus / U.S. National Library of Medicine, [6] U.S. FDA
What does WHO’s conditional guidance mean?

WHO supports considering GLP-1 treatment for adult obesity, excluding pregnancy, within continuing care. Its recommendations are conditional because questions remain about long-term evidence, stopping treatment, cost and access. WHO discussed health-system preparation again in March 2026. International guidance does not automatically establish a product’s approval in Thailand.
What to tell the prescribing clinician
Semaglutide carries a thyroid-tumour warning based on animal studies; the human risk is uncertain. Tell the clinician about relevant thyroid cancer or MEN2 history. The warnings for the actual product prescribed must be checked.
- Your health goal, measurements, weight history and other health conditions.
- All medicines, supplements and weight-loss products you take.
- Pregnancy plans, breastfeeding and upcoming operations or procedures.
- Relevant pancreatic, gallbladder, kidney, digestive and family medical history.
Sources: [3] NIDDK / NIH, [4] MedlinePlus / U.S. National Library of Medicine
Side effects that need attention

Semaglutide can cause nausea, vomiting, diarrhoea or constipation. Contact the prescriber if symptoms are severe or persist. Inability to drink needs assessment for dehydration. Do not increase a dose to speed up results.
Persistent severe abdominal pain, particularly pain reaching the back, or facial or throat swelling with breathing difficulty needs immediate medical help. These examples are not a complete list of risks for every medicine.
Sources: [4] MedlinePlus / U.S. National Library of Medicine
Plan for follow-up and cost
Weight may increase after stopping weight-management medicines. Discuss how benefits and side effects will be assessed and what will happen if treatment becomes unaffordable or difficult to tolerate.
Useful questions include: What is my health goal? When will we review progress? Who do I contact about side effects? How will care continue if the medicine stops? Another person’s results cannot predict your own.
Sources: [1] WHO, [3] NIDDK / NIH
Check the source of medicines
WHO warns that demand has encouraged falsified and substandard products. Use a verifiable prescribing and supply route. Avoid sellers who will not identify the product, its source or the clinician responsible for care.
Our general treatment service can discuss your overall health and appropriate next steps. Choose health checks for a clinical reason rather than assuming every package is required. If you already have diabetes, read about monitoring blood sugar and HbA1c.
Good to know: This guide is education about medicines, not a stock announcement or an offer of GLP-1 treatment. Ask about the clinic’s service scope before booking.
Sources: [1] WHO, [3] NIDDK / NIH
Frequently asked questions
The amount you want to lose is not enough to decide. Discuss the indication, health goal, risks and alternatives. Weight-management medicine should not be used for appearance alone.
Related services
Related articles
Sources
- [1] WHO issues global guideline on the use of GLP-1 medicines in treating obesity WHOPublished 1 December 2025Accessed 9 October 2026
- [2] Obesity: GLP-1 therapies WHOAccessed 9 October 2026
- [3] Prescription Medications to Treat Overweight & Obesity NIDDK / NIHAccessed 9 October 2026
- [4] Semaglutide Injection MedlinePlus / U.S. National Library of MedicineAccessed 9 October 2026
- [5] WHO Director-General’s opening remarks: 5 March 2026 WHOPublished 5 March 2026Accessed 9 October 2026
- [6] FDA Approves New Medication for Chronic Weight Management (tirzepatide mechanism) U.S. FDAPublished 8 November 2023Accessed 9 October 2026
This content is general information and does not replace an examination, diagnosis or personal advice from a doctor. Published 9 October 2026
How we select sources and handle corrections
